Skip to main content
. 2024 Aug 20;15:1437267. doi: 10.3389/fimmu.2024.1437267

Figure 1.

Figure 1

Trial profile. IIV4: quadrivalent split-virion inactivated influenza vaccine. PPV23: 23-valent pneumococcal polysaccharide vaccine. The dashed lines represent the 95% CI lower boundary of 0.5 for GMT ratios and -10% for the seroconversion rate differences.